Menu
Washingtoner
  • Home
  • Artificial Intelligence
  • Health
  • Technology
  • Entertainment
  • Software
  • Real Estate
  • Business
  • Education
Washingtoner

Study Finds Lotus Vaping Technologies' Flavored E-Liquids Reduce Smokers' Cigarettes Per Day at Significantly Higher Rate Than Tobacco Flavor
Washingtoner/10239600

Trending...
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • Spokane: City And County Seek Federal Grant to Plan for Road Network Wildfire Resilience
A rigorous three-month longitudinal cohort study of several of flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

BOISE, Idaho - Washingtoner -- Lotus Vaping Technologies, LLC, a Boise, Idaho-based manufacturer of bottled e-liquids for use in electronic nicotine delivery systems ("ENDS") or e-cigarettes, announced today that a rigorous three-month longitudinal cohort study of several of its FreenomsTM branded flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

The three-month study conducted from March 2023 to August 2023 involved 451 randomly assigned participants who were cigarette smokers, 221 of which were assigned to a control group that used only tobacco-flavored e-liquid, and 230 of which were assigned to a group that could use any of five different non-tobacco flavored bottled e-liquids, including Lotus's proprietary BluenomenomTM, StranomenonTM, X2 Cactus Jackfruit, and White Peach Raspberry flavors.

More on Washingtoner
  • Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
  • Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
  • Spokane: City Details Veterans Day Schedule
  • The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
  • Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category

At the end of three months, the average number of cigarettes smoked per day ("CPD") by the tobacco-flavored control group was reduced from 12.51 to 9.54, for a 23.72% reduction, while for the flavored e-liquid group, the average CPD was reduced from 11.70 to 6.88, for a 41.25% reduction.  The reduction in cigarettes smoked per day was thus 73.9% greater for the flavored group than the tobacco-flavored group. The study results also demonstrated statistically significant differences between several of Lotus's flavored e-liquids when compared head-to-head against tobacco-flavored e-liquids with respect to CPD reduction.

Additionally, a full 14.3% of study participants in the flavored group had quit smoking cigarettes altogether by the end of the third month—a rate that is substantially higher than that typically reported for FDA-approved nicotine replacement therapy products (9.0%).

Lotus's Director of Sales, Mike Larsen stated, "We are very excited about these study results. This study demonstrates what users of our products have known anecdotally for a long time—flavored e-liquids are more effective than tobacco flavor at promoting cigarette smoking reduction and cessation. The FDA has been asking for this data—we hope it will now take it into consideration when reviewing our premarket tobacco product applications and grant our flavored products the marketing authorizations that they deserve."

More on Washingtoner
  • Washington Nurse Introduces Nightingale Care Hub to Help Families Organize Care
  • HIRO Ostomy Belt Launch by Richard O'Hamill
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Flags Lowered for Spokane County Sheriff Deputies
  • Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand

About Lotus Vaping Technologies, LLC – Creator of NomenonsTM E-Liquids

Established in 2013, Lotus is a leading manufacturer and wholesaler of premium e-liquids in the United States providing a diverse range of vapor products for sale to adult consumers that satisfy a wide variety of consumer preferences and serve as alternatives to combustible cigarettes. Lotus is committed to responsible manufacturing processes and utilizes only the highest standards in its e-liquid production.

Media Contact
Mike Larsen
mike@lotusecigs.com


Source: Lotus Vaping Technologies, LLC
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Spokane: City And County Seek Federal Grant to Plan for Road Network Wildfire Resilience
  • The Great Junk Hunt Returns to Monroe: Kick Off Your Holiday Shopping at the Ultimate Vintage Treas
  • AI Trading Agents Track Aerospace and Defense US Stocks Amid Rising Technology Investment (SATS, GILT, TSAT, IREN, JOBY, LUNR)
  • KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
  • Evluma's RoadMax Edge Roadway Luminaires Earn DarkSky Approved Status
  • Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • Tacoma: Public Hearing for Off-Street Parking Code Update Set for December 1
  • Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
  • Spokane: SPD Makes an Arrest in Yesterday's Early Morning Shooting
  • Spokane: Mayor Brown Introduces 2027-2028 Budget Proposal
  • Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
  • IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
_catLbl0 _catLbl1

Popular on Washingtoner

  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 237
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 201
  • Final Week to Register for Free Spokane Community Conference - 187
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 173
  • Author Robert A. Robinson Introduces Anarchy at the AYP: - 132
  • LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement - 123
  • Kent Youth and Family Services Announces Sale of Watson Manor - 113
  • Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX - 107
  • Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms - 107
  • Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon

Similar on Washingtoner

  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Haven Treatment Center Pays It Forward with Donation of 150 Food Boxes and Gift Cards to Evergreen
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute